This is to inform you that the company has entered into Business Transfer Agreement ("BTA") on 30th August, 2024 around 11:00 AM with inter-alia, Thyrocare Technologies Limited (Thyrocare). By this agreement, our company will be transferring and selling its Diagnostics and pathological services business to Thyrocare as a going concern (on slump sale basis). Th said transfer is subject to fulfilment of the Condition Precedent ("CP").